Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev …
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than …
The US Food and Drug Administration’s (FDA’s) pilot scheme to expedite the review of US-made generic medicines is welcomed but …
France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline …
Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand …
Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand …
AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to …
Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset, …
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every …
Bavarian Nordic’s board of directors has urged shareholders to accept a sweetened takeover offer as the potential sale of the …
Tubulis has completed a Series C financing round, securing €308m ($361m) that will primarily be directed towards advancing clinical development …
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m …
A new report from the World Health Organization (WHO) has highlighted the global healthcare burden of neurological disorders. In the latest …
Kirkland & Ellis has secured the foremost position as a legal adviser in the mergers and acquisitions (M&A) sector in …
Goldman Sachs has secured the top spot as the leading financial adviser in mergers and acquisitions (M&A) based on deal …
